



May 27, 2024

To

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Tel: 022 - 2272 1233 /4
Fax: 022 - 22721919

Ref: Aragen Life Sciences Limited

Scrip Code: 973783

ISIN: INE483I07010

Sub: Publication of Extract of Financial Results in an English national daily newspaper

In compliance with Regulation 52 (8) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, the Company has, on Saturday, 25th May 2024, published in 'Business Standard', an English national daily newspaper, the extract of the Financial Results for the quarter and the year ended 31st March 2024. A copy of the newspaper cutting is enclosed herewith.

Please take on your records.

For Aragen Life Sciences Limited

Ramakrishna Kasturi

Company Secretary & Compliance Officer

ARAGEN LIFE SCIENCES LIMITED

(formerly known as Aragen Life Sciences Private Limited)

CIN: U74999TG2000PLC035826

Registered and Corporate Office: Plot 28A, IDA Nacharam,
Hyderabad, Telangana-500076, India

Tel: +91 40 6692 9999 F: +91 40 6692 9900

Email id: compliances@aragen.com, website:www.aragen.com

**Extract of consolidated financial results for the quarter and year ended 31 March 2024**

(amount in ₹ million)

S. No.	Particulars	Quarter ended			For the year ended	
		31 March 2024	31 December 2023	31 March 2023	31 March 2024	31 March 2023
		Audited	Unaudited	Audited	Audited	Audited
1	Total Income from operations	4,142.58	4,394.70	4,353.98	16,575.77	17,366.01
2	Net Profit / (Loss) for the period (before tax, Exceptional and/or Extraordinary items)	485.52	779.64	871.97	2,248.33	3,065.50
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	485.52	779.64	871.97	2,248.33	3,065.50
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	331.94	586.22	640.63	1,601.04	2,198.71
5	Total Comprehensive Income for the period/Year [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	335.34	606.94	870.21	1,736.93	2,031.62
6	Paid up Equity Share Capital (Face value of ₹ 10/- each)	2,044.14	2,044.14	2,044.14	2,044.14	2,044.14
7	Reserves (excluding Revaluation Reserve)	11,001.31	10,638.06	9,707.37	11,001.31	9,707.37
8	Securities Premium Account	0	0	0	0	0
9	Net worth	13,045.45	12,682.20	11,751.51	13,045.45	11,751.51
10	Paid up Debt Capital	6,454.70	6,011.12	5,285.39	6,454.70	5,285.39
11	Outstanding Redeemable Preference Shares	N.A.	N.A.	N.A.	N.A.	N.A.
12	Debt Equity Ratio	0.49	0.47	0.45	0.49	0.45
13	Earnings Per Share (EPS) (Face value of ₹ 10 each fully paid)*					
	Basic EPS (Rs)	1.64	2.88	3.44	7.83	10.72
	Diluted EPS (Rs)	1.60	2.84	3.40	7.71	10.59
14	Capital Redemption Reserve	--	--	--	--	--
15	Debenture Redemption Reserve	200.00	200.00	200.00	200.00	200.00
16	Debt Service Coverage Ratio*	1.20	5.09	0.99	1.18	3.18
17	Interest Service Coverage Ratio*	4.74	7.20	12.85	5.83	8.88

*Quarter ended ratios are not annualised.

*EPS not annualised for the quarter ended.

NOTE: The Stock Exchange available in India Limited

Chennai
May 23,

Sl. No.

1 Total

2 Net P (before)

3 Net P (after)

4 Net P (after)

5 Total (Company and other)

6 Equity

7 Earnings

discontinued

i) Balance

ii) Dividend

Note: The information is for reference only.

Place: Chennai
Date: 23/05/2024

Notes:

1. The above is an extract of the detailed format of quarterly/annual financial results filed with the Stock Exchange(s) under regulation 52 of the Listing Regulations. The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on 23 May 2024. These Financial Results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act 2013 read with the relevant rules there under and the other accounting principles generally accepted in India.
2. For the other line items referred in Regulation 52(4) of the LODR Regulations, pertinent disclosures have been made to the stock exchange, BSE Limited, and can be accessed at www.bseindia.com. The full format of the quarterly/annual financial results including detailed notes thereon are available on the websites of the stock exchange- BSE Limited at www.bseindia.com and the Company at www.aragen.com.
3. During the year ended 31 March 2022, the Group had issued 2,000 rated, listed, redeemable, Non-convertible Debentures (NCDs) of face value ₹1,000,000 each for a total amount of ₹ 2,000 million on a private placement basis. These NCDs have been listed on the Stock Exchange (BSE Limited) with effect from 14 February 2022. The NCDs are repayable at the end of 36 months from the date of allotment and carry an annual interest rate of 7.75% per annum due on 11 February of every year.
4. In terms of regulation 54(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the NCDs are secured by first charge on Property, plant & equipment, movable CWIP including immovable property at Mallapur unit with minimum asset cover of 1.25x.
5. During the quarter and year ended 31 March 2024, the Company had not received any complaints from the NCD holders and there has been no complaint pending for redressal at the beginning or at the end of the quarter. The equity shares of the Company are not listed on any Stock Exchange.
6. The statutory auditors of the Group ("B S R and Co") have carried out an audit of the above consolidated financial results for the quarter and year ended 31 March 2024 and have issued an unmodified audit report. The audit report of the Statutory auditors was filed with the BSE Limited and also is available on the Company's website.
7. Figures for the quarter ended 31 March 2024 and 31 March 2023 represents the balancing figure between the audited figures in respect of the full financial year and the unaudited year to date figures up to the third quarter of the respective financial years.
8. During the quarter, the Board of Directors granted 3,17,615 stock options under Employee Stock Option Scheme 2022 with an exercise price of ₹10 per share. The vesting period for the grants issued during the year is one year from the date of grant.
9. The Board of Directors of the Company have recommended a final dividend of ₹2 per share on 23 May 2024 for the financial year ended 31 March 2024. Such final dividend is subject to approval of the shareholders.

For Aragen Life Sciences Limited

Sd/-

Manmahesh Kantipudi

Whole-time Director & CEO

DIN: 05241166

Date : 23 May 2024

Place : Hyderabad